The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Pathogenesis of Nonalcoholic Steatohepatitis
Open accessAbstract
Nonalcoholic steatohepatitis (NASH) is a necro-inflammatory response that ensues when hepatocytes are injured by lipids (lipotoxicity). NASH is a potential outcome of nonalcoholic fatty liver (NAFL), a condition that occurs when lipids accumulate in hepatocytes. NASH may be reversible, but it can also result in cirrhosis and primary liver cancer. We are beginning to learn about the mechanisms of progression of NAFL and NASH. NAFL does not inevitably lead to NASH, because NAFL is a heterogeneous condition. This heterogeneity exists because different types of lipids with different cytotoxic potential accumulate in the NAFL, and individuals with NAFL differ in their ability to defend against lipotoxicity. There are no tests that reliably predict which patients with NAFL will develop lipotoxicity. However, NASH encompasses the spectrum of wound-healing responses induced by lipotoxic hepatocytes. Differences in these wound-healing responses among individuals determine whether lipotoxic livers regenerate, leading to stabilization or resolution of NASH, or develop progressive scarring, cirrhosis, and possibly liver cancer. We review concepts that are central to the pathogenesis of NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
The mechanisms of Hedgehog signalling and its roles in development and disease
Briscoe, J., & Thérond, P. P. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3598 · Cited by 1,751
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,293
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Cited by
Pyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., & Ramnarain, D. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00980-1 · Cited by 897
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
Tsurusaki, S., Tsuchiya, Y., Koumura, T., Nakasone, M., Sakamoto, T., Matsuoka, M., Imai, H., Yuet-Yin Kok, C., Okochi, H., Nakano, H., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1678-y · Cited by 529
Seidman, J. S., Troutman, T. D., Sakai, M., Gola, A., Spann, N. J., Bennett, H., Bruni, C. M., Ouyang, Z., Li, R. Z., Sun, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.001 · Cited by 443
Non-alcoholic fatty liver disease
Neuschwander-Tetri, B. A. (2017) · BMC Medicine · doi:10.1186/s12916-017-0806-8 · Cited by 451
Xu, B., Jiang, M., Chu, Y., Wang, W., Chen, D., Li, X., Zhang, Z., Zhang, D., Fan, D., Nie, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.040 · Cited by 426
Guo, X., Yin, X., Liu, Z., & Wang, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415489 · Cited by 412
Emerging roles of SIRT1 in fatty liver diseases
Ding, R.-B., Bao, J., & Deng, C.-X. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19370 · Cited by 359
Kumar, S., Duan, Q., Wu, R., Harris, E. N., & Su, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113869 · Cited by 351
Luo, W., Xu, Q., Wang, Q., Wu, H., & Hua, J. (2017) · Scientific Reports · doi:10.1038/srep44612 · Cited by 282
Ibrahim, S. H., Hirsova, P., & Gores, G. J. (2018) · Gut · doi:10.1136/gutjnl-2017-315691 · Cited by 278
PPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Li, X., Wang, T., Huang, X., Li, Y., Sun, T., Zang, S., Guan, K., Xiong, Y., Liu, J., & Yuan, H. (2020) · Liver International · doi:10.1111/liv.14428 · Cited by 273
Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis
Cai, B., Dongiovanni, P., Corey, K. E., Wang, X., Shmarakov, I. O., Zheng, Z., Kasikara, C., Davra, V., Meroni, M., Chung, R. T., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.013 · Cited by 266
“In view of the importance of hepatic fibrosis in the clinical course of NASH, a future goal will be to determine how the macrophage MerTK-TGFβ1 revealed here might be integrated with other pathways leading to HSC activation in NASH, including those involving inflammation, cell death, and pathways involving members of…”
BackgroundHepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis
Zhu, C., Kim, K., Wang, X., Bartolome, A., Salomao, M., Dongiovanni, P., Meroni, M., Graham, M. J., Yates, K. P., Diehl, A. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0344 · Cited by 250
Self-citationHou, X., Yin, S., Ren, R., Liu, S., Yong, L., Liu, Y., Li, Y., Zheng, M., Kunos, G., Gao, B., et al. (2021) · Hepatology · doi:10.1002/hep.31658 · Cited by 223
Farrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178
Macrophage-derived osteopontin (SPP1) protects from nonalcoholic steatohepatitis
Han, H., Ge, X., Komakula, S. S. B., Desert, R., Das, S., Song, Z., Chen, W., Athavale, D., Gaskell, H., Lantvit, D., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.03.228 · Cited by 155
Understanding bile acid signaling in diabetes: From pathophysiology to therapeutic targets
Ferrell, J. M., & Chiang, J. Y. L. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0043 · Cited by 139
Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development
Kantono, M., & Guo, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01132 · Cited by 133
Schulien, I., Hockenjos, B., Schmitt-Graeff, A., Perdekamp, M. G., Follo, M., Thimme, R., & Hasselblatt, P. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0239-8 · Cited by 111
El-Derany, M. O., & AbdelHamid, S. G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114624 · Cited by 64
Jang, W., & Song, J. S. (2023) · Diagnostics · doi:10.3390/diagnostics13111852 · Cited by 55
MASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
“The main driver of MASLD is obesity and adiposopathy (6), as well as the metabolic disturbances that come with it such as insulin-resistance/type 2 diabetes mellitus (T2DM), dyslipidemia, and hypertension (7).”
BackgroundSelf-citationLiu, D., Wang, K., Li, K., Xu, R., Chang, X., Zhu, Y., Sun, P., & Han, X. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1672-4 · Cited by 35
MMP10 alleviates non-alcoholic steatohepatitis by regulating macrophage M2 polarization
Chang, L., Gao, J., Yu, Y., Liao, B., Zhou, Y., Zhang, J., Ma, X., Hou, W., Zhou, T., & Xu, Q. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111045 · Cited by 20
Beyazal Polat, H., Beyazal, M., Arpa, M., Kızılkaya, B., Ayaz, T., Gündoğdu, Ö. L., Konur, K., Polat, Z., Beyazal Çeliker, F., & Atasoy, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103513 · Cited by 13
“MASLD is characterized by hepatic steatosis in the presence of cardiometabolic risk factors and, by definition, it excludes other causes of liver fat accumulation such as excessive alcohol consumption or viral hepatitis [3,4].”
St. Rose, K., Yan, J., Xu, F., Williams, J., Dweck, V., Saxena, D., Schwabe, R. F., & Caviglia, J. M. (2022) · Hepatology Communications · doi:10.1002/hep4.2035 · Cited by 14
Yu, H.-H., Hsieh, M.-C., Wu, S.-Y., Sy, E. D., & Shan, Y.-S. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s190631 · Cited by 9
“Accumulating evidence demonstrates that NASH is a multifactorial disease comprising genetic predisposition, gut-derived endotoxin and ethanol, intestinal microbiota, environmental factors, cell apoptosis, and hepatic autophagy.(22) In this study, we”
Background
Metadata
- Authors
- Machado, M. V., & Diehl, A. M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 150
- Issue
- 8
- Pages
- 1769-1777
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2283843704
- Cited by
- 539
- References
- 75
- FWCI
- 29.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.